Gastric cancer: high TIL levels show prognostic value

  • Zhang D & al.
  • Front Immunol
  • 1 Jan 2019

  • curated by David Reilly
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • In patients with gastric cancer, high levels of tumor-infiltrating lymphocytes (TILs) in the tumor microenvironment are associated with positive prognosis.

Why this matters

  • TILs may assist in selecting patients who may derive benefit from immune checkpoint inhibitor therapy.
  • No scoring consensus exists for the evaluation of TIL in gastric cancer.

Study design

  • Study to investigate a relationship between TIL levels and OS in 833 patients with gastric cancer.
  • Funding: National Natural Science Foundation of China; Key R&D Project of Science and Technology Department of Jiangsu Province; Changzhou Health and Planning Commission Youth Talent Science and Technology Project.

Key results

  • 78.17±2.00 months average survival with TILhi vs 41.21±2.09 months with TILlow (X2=148.762; P<.001>
  • Superior prognosis with TILhi vs TILlow per Kaplan-Meier analysis (X2=174.77; P<.001>
  • In multivariate Cox regression analysis, TILhi was an independent prognostic indicator for OS (HR, 0.431; 95% CI, 0.347-0.534; P<.0001>
  • A nomogram was created incorporating TIL, histological grade, tumor size, nerve invasion, age, and pathological tumor and lymph node (pTN) stage; on validation, the nomogram demonstrated a greater concordance for predicting 3- and 5-year OS (C-index, 0.760; 95% CI, 0.704-0.815) vs pTN stage (C-index, 0.720) and TIL (C-index, 0.633).

Limitations

  • Retrospective data.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit